Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABSK061 in Advanced Solid Tumors
NCT05244551Phase 1Recruiting
- Sponsor
- Abbisko Therapeutics
- Start
- Jun 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of lavengratinib in solid tumor, urothelial carcinoma (UC) and cholangiocarcinoma (CCA), sponsored by Abbisko Therapeutics. Primary endpoints: Incidence of Dose-Limiting Toxicities and Incidence and Severity of Adverse Events. Started Jun 2022; status: recruiting.
02
Drugs
lavengratinib
03
Conditions
solid tumorurothelial carcinoma (UC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05244551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244551.